CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation

Brien K Haun; Chih-Yun Lai; Caitlin A Williams; Teri Ann S Wong; Michael M Lieberman; Laurent Pessaint; Hanne A Elyard; Axel T Lehrer

This article is a Preprint

Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.

CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation

Brien K Haun; Chih-Yun Lai; Caitlin A Williams; Teri Ann S Wong; Michael M Lieberman; Laurent Pessaint; Hanne A Elyard; Axel T Lehrer.

Affiliation

Brien K Haun; University of Hawaii at Manoa / John A. Burns School of Medicine
Chih-Yun Lai; University of Hawaii at Manoa / John A. Burns School of Medicine
Caitlin A Williams; University of Hawaii at Manoa / John A. Burns School of Medicine
Teri Ann S Wong; University of Hawaii at Manoa / John A. Burns School of Medicine
Michael M Lieberman; University of Hawaii at Manoa / John A. Burns School of Medicine
Laurent Pessaint; BIOQUAL, Inc.
Hanne A Elyard; BIOQUAL, Inc.
Axel T Lehrer; University of Hawaii at Manoa / John A. Burns School of Medicine

Preprint in English | bioRxiv | ID: ppbiorxiv-220715

Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article

ABSTRACT

ABSTRACT

The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT or Alhydrogel. CoVaccine HT induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralising antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.

License

cc_no

Fulltext

Add to My VHL

XML

Search on Google

Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2020 Document type: Preprint

Fulltext

Add to My VHL

XML

Search on Google

Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2020 Document type: Preprint